William P. Forbes, the Chief Development Officer at Heron Therapeutics, Inc., has made significant stock transactions that reflect his ongoing commitment to the company. In a recent SEC filing, Forbes reported acquiring 3,874 shares of common stock on October 19, 2026. This acquisition is part of a series of transactions that highlight Forbes' investment in Heron Therapeutics, which is focused on developing innovative treatments in the pharmaceutical preparations sector.
Heron Therapeutics, based in San Diego, California, specializes in pharmaceutical preparations. The company is publicly traded under the ticker symbol HRTX and is incorporated in Delaware. The recent filing, dated October 21, 2026, is part of a series of disclosures made by Forbes, indicating his active role in the company's financial landscape.
The filing details two non-derivative transactions and one derivative transaction. Forbes acquired 3,874 shares of common stock and an additional 1,102 shares at a price of $0.36 per share. Following these transactions, Forbes now holds a total of 245,047 shares of common stock directly. Additionally, he has 19,372 shares from restricted stock units, which vest in quarterly installments beginning January 19, 2024.
"Each restricted stock unit represents a contingent right to receive one share of common stock," the filing noted.
These transactions may affect shareholders and potential investors by signaling Forbes' confidence in the company's direction and future performance. As the pharmaceutical industry continues to evolve, such insider transactions can provide insights into the company's health and prospects.
Details were not available in the SEC filing regarding what happens next for Forbes or Heron Therapeutics following these transactions. However, the ongoing reporting of stock transactions by Forbes suggests that he remains actively engaged in the company's strategic direction.